0000905718-20-000098.txt : 20200131
0000905718-20-000098.hdr.sgml : 20200131
20200131201517
ACCESSION NUMBER: 0000905718-20-000098
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200129
FILED AS OF DATE: 20200131
DATE AS OF CHANGE: 20200131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sinclair Andrew
CENTRAL INDEX KEY: 0001762451
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37490
FILM NUMBER: 20566637
MAIL ADDRESS:
STREET 1: C/O SOLENO THERAPEUTICS INC.
STREET 2: 1235 RADIO ROAD, SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sierra Oncology, Inc.
CENTRAL INDEX KEY: 0001290149
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ? 885 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 3E8
BUSINESS PHONE: 604-558-6536
MAIL ADDRESS:
STREET 1: 2150 ? 885 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 3E8
FORMER COMPANY:
FORMER CONFORMED NAME: ProNAi Therapeutics Inc
DATE OF NAME CHANGE: 20040513
4
1
sierraonco_fm4jan292020.xml
X0306
4
2020-01-29
0
0001290149
Sierra Oncology, Inc.
SRRA
0001762451
Sinclair Andrew
C/O SIERRA ONCOLOGY, INC.
2150-885 WEST GEORGIA STREET
VANCOUVER
A1
V6C 3E8
BRITISH COLUMBIA, CANADA
1
0
0
0
Common Stock
2020-01-29
4
C
0
871125
0
A
876542
I
See footnotes
Series A Convertible Voting Preferred Stock
2020-01-29
4
C
0
11500
D
Common Stock
871125
0
I
See footnotes
The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split.
Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date.
Consists of 11,500 shares of Series A Preferred Stock held by ABV VII which are convertible into an aggregate of 871,125 shares of Common Stock, as adjusted for the Reverse Split.
/s/ John Heard, as attorney-in-fact
2020-01-31